A Phase I Trial Evaluating the Effect of the Addition of HMGCoA-Reductase Inhibition With Pravastatin to Salvage Chemotherapy Idarubicin-HDAC in Patients With Relapsed or Refractory Acute Myelogenous Leukemia.
Latest Information Update: 18 Sep 2021
Price :
$35 *
At a glance
- Drugs Cytarabine; Idarubicin; Pravastatin
- Indications Acute myeloid leukaemia
- Focus Adverse reactions
- 21 Sep 2010 Biomarkers information updated
- 20 Sep 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 07 Sep 2005 New trial record.